Stopped: Sponsor request to terminate study due to enrollment numbers
Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Relationship between treatment with erdafitinib and clinical response
Timeframe: Time to progression will vary for each patient. We expect most patients to progress on erdafitinib within 2 to 15 months from baseline